**Novel Therapeutic Approach Against Neurodegeneration**

**Aim**
- To provide an improved therapy for polyglutamine (polyQ)-induced neurodegeneration

**Features**
- Novel isolated peptide against mRNA toxicity
- Combined therapeutic regimen targeting BOTH protein and mRNA toxicities that cause the neurodegeneration

**Applications**
- Huntington's disease
- Spinocerebellar ataxia (SCA)
- Parkinson's Disease

**Related Patents**
- US14/293,816
- Priority date: 03/06/2013

---

**CUHK Tech ID:** P-2013-0512  |  **For further information, please contact:**
Dr. Stephen LAM (stephen@cuhk.edu.hk) +852-3943 9398
Dr. Ken CHOW (kenchow@cuhk.edu.hk) +852-3943 1453

---

**Gene transcription**

<table>
<thead>
<tr>
<th>Gene transcription</th>
<th>Protein translation</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCLP3</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>RNA toxicity</th>
<th>Protein toxicity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Expanded CAG RNA</td>
<td>Expanded polyQ protein</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Neurodegeneration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control NCLP3 QBP1 NCLP3 +QBP1</td>
</tr>
</tbody>
</table>

**Average number of fibres per neuron**

- Normal phenotype
- Neurodegenerative phenotype